Asset Details
Do you wish to reserve the book?
Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
Do you wish to request the book?
Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
2015
Overview
[...]to introduce the FOLFIRINOX therapy as early as possible in Japan, we used the same dosing regimen as that in the ACCORD11 study. When we planned this trial, we already knew the results of the ACCORD11 study. [...]we considered that it would be more appropriate to assess the safety of the FOLFIRINOX regimen on a large cohort of Japanese patients rather than to assess dose limiting toxicity in 3–6 patients with an escalation of the patient doses by conducting a typical phase I study. [...]the response rate that was the primary endpoint was comparable to that of the ACCORD11 study.
Publisher
John Wiley & Sons, Inc,John Wiley & Sons, Ltd
